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1. Introduction
Traditional Chinese medicine (TCM), an age-old healthcare system derived from China, is a
mainstream medicine in China and is also popular in many other parts of the world [1-3]. Due to
historic reasons, the scientific base of TCM awaits consolidation but emerging evidence has be‐
gun to illustrate TCM as an area of important medical rediscoveries. For example, the 2011 Lask‐
er-DeBakey Clinical Medical Research Award was awarded to Youyou Tu for the discovery of
Chinese herb-derived artemisinin, a drug for malaria that has saved millions of lives across the
globe [4,5] and the 7th Annual Szent-Györgyi Prize was awarded to Zhen-Yi Wang and Zhu Chen
for their TCM research that led to the successful development of a new therapeutic approach to
acute promyelocytic leukaemia. These award-winning projects were both conducted well be‐
fore the human genome was decoded and when information technology was in infancy. What
has TCM to offer in the post-genomic era and the Information Age? To address this important
question, the GP-TCM project kicked in as the 1st EU-funded EU-China collaboration dedicated
to applying emerging technologies to TCM research [6,7]. Besides the consensus that omics and
systems biology approaches will likely play major roles in addressing the complexity of TCM
[7-9], more than half GP-TCM consortium members who responded to a consortium survey also
cast votes of confidence in network pharmacology in TCM research [7]. Then, what is network
pharmacology? What is the state of the art of this technology in modern pharmacological and
toxicological studies, and finally, what are its possible roles in TCM research?
2. What is network pharmacology?
Network could be used to refer to any interconnected things or people in a virtual or actual
net-like structure. For example, in information technology, anatomy, systems biology and
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social science, it could refer to interconnect computers (e.g. intranet or internet), bodily
structures (e.g. neurons and vessels), molecules (e.g. genes, mRNAs, proteins, metabolites),
or an association of individuals having a common interest, formed to provide mutual assis‐
tance, helpful information, or the like (e.g. the FP7 GP-TCM consortium) [6,7], respectively.
In network pharmacology, “network” doesn’t mean that a group of scientists who share
similar interests are interconnected, as the FP7 GP-TCM consortium and the famous Poly‐
math Project of mathematicians do [7,10], nor does it refer to interconnected anatomical
structures or computers. Instead, the concept is built on the belief that targeting multiple no‐
des in interconnected molecular systems, rather than individual molecules, could lead to
better efficacy and fewer adverse effects [11,12]. It integrates polypharmacology [13,14] and
computational pharmacology or in silico pharmacology [15] and is based on the principles
and objectives of systems pharmacology [16,17]. Thus, network pharmacology could be re‐
garded as the technical route to the ultimate ideal of systems pharmacology, in which drugs
are designed to benefit a human being as an integrative system, taking into consideration
the complex dynamics of interconnected organic and molecular systems.
In brief, network pharmacology is based on the principles of network theory and systems biolo‐
gy. Graph or network theory is a branch of mathematics, which is concerned with characteristics
of networks (“webs”) of interacting objects. Systems biology, as the name implies, deals with
complex and comprehensive living systems involving a finite number of hierarchically ordered
components, which form interacting networks affected by, and responding to, various pertur‐
bations within the system itself and from the environment [18]. Typical for the network's re‐
sponse to perturbations is the return of a system to a previous state or the adoption of a new
homeostasis. 'Systems biology is an analytical approach to investigating relationships among
system's components in order to understand its emergent, i.e. network-level properties' [19].
Emergent properties, e.g. homeostasis, are higher-level characteristics of complex systems,
which are difficult to understand and predict just by studying a few components at a time in iso‐
lation. In medicine and pharmacology, when traditional approaches are mostly concerned with
individual molecules or pathways, systems biology aims at integration of biological complexity
at all levels of biological organisation, be it cell, organ, organism, or population.
Although polypharmacology and computational pharmacology have a relatively long histo‐
ry, network pharmacology and systems pharmacology are emerging new concepts that were
only developed in the past 5-7 years. In October 2011, the Quantitative and Systems Pharma‐
cology Working Group of the US National Institutes of Health published a white paper enti‐
tled Quantitative and Systems Pharmacology in the Post-Genomic Era: New Approaches to
Discovering Drugs and Understanding Therapeutic Mechanisms, which provided a general re‐
port-level overview of the field from the perspectives of drug development and therapy and
listed a number of important research goals for the future. It may be of interest to recapitu‐
late one of the working definitions of the report:
“The goal of Quantitative and Systems Pharmacology is to understand, in a precise, predictive manner, how drugs modulate cellu‐
lar networks in space and time and how they impact human pathophysiology.”
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3. Principles of systems biology and network pharmacology
Detailed descriptions of principles of networks in systems biology can be found in several arti‐
cles and reviews [20-22]. Herein, only a short presentation of the most important features is
provided. Some most important characteristics and their biological examples are shown in Ta‐
ble 1. Network is formed by nodes (basic building blocks), their connections (‘edges’) and mod‐
ules (a collection of nodes with a higher number of connections with each other in comparison
with the rest of the network), and is characterised by a number of topological features defining
relationships between network objects. There is a hierarchy in the properties of nodes in that
some of them (“hubs”) are more central with a high number of connections to other nodes
whereas the majority of nodes have only one or a few connections at the most with other nodes.
Bridging nodes connect two other nodes or modules in the network. As a consequence of non-
random nature of biological networks, these networks are called “scale-free” in the network
theory; Barabasi & Oltvai also referred to them as 'scale-rich' [21].
Network characteristics Definition and explanation Biological entities and functions
(examples)
Node Basic component interacting (pair-wise) with other
node(s)
• Small-molecular substrates (metabolic
network)
•Genes (genetic regulatory network)
•Proteins (protein-protein network)
Edge (link, connection) Connection between two nodes • Connection may be physical, regulatory,
genetic interaction;
• Metabolic network: enzyme-catalysed
reactions
• Genetic regulatory network: expression
data
Node degree or connectivity Number of links to other nodes; “hubs” are nodes with a
large number of connections, but there are only a few of
them in any network
•Associated with topological robustness of
biological networks, i.e. small degree
nodes are more “disposable” than hubs
Path length The average separation between arbitrarily chosen
nodes
• Proximal and distal nodes in a functional
module
Clustering coefficient A measure of grouping tendency of the nodes • Points to a motif and/or module
Motif and motif clusters Recurring, significant patterns of interconnections • Elementary building blocks (sub-
networks) of biological networks
Network module A set of nodes with high internal connectivity • Subunits of a protein complex; dynamic
functional unit, e.g. metabolic pathway,
signalling cascade
Bridging node A node bridging the shortest path between two other
nodes or modules within a network
• A node linking two functional units
(“crosstalk” point; a potential drug target),
etc.
Bridging centrality Measure for connectivity within a network for the
measured node
Table 1. Important network characteristics in biological and pharmacological networks [18,19,21]
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Complex networks possess characteristics that are of considerable importance for the inves‐
tigation of drug discovery and drug treatment. Emergent properties of networks have al‐
ready been mentioned earlier. Recently, there has been some theoretical and experimental
work on strong and weak emergent features of networks [23]. Network robustness is a very
important feature, which refers to the ability of a network to respond to external or internal
perturbations [21]. Biological networks demonstrate remarkable robustness, which is at least
partially based on a scale-free assembly: failure of nodes with few connections (small degree
nodes), which form the majority of nodes, does not affect the integrity of the network,
whereas failure of a few key hubs disintegrates the network. This latter phenomenon also is
the basis of vulnerability of a network, if key hubs are targets of disruptive influences.
It is perhaps fair to mention and emphasise that many network-level emergent properties
are important concepts in physiology, which is a system-level discipline. Concepts such as
homeostasis, set-points, regulation, feedback control and redundancy have been in physiol‐
ogy for a long time to explain and model the interactions between cells, organs, systems and
organisms [24]. Many of these system-level concepts have direct correspondences or rela‐
tives in network systems biology.
4. How to build a network?
Building a network involves two opposite approaches: a bottom-up approach on the basis of
established biological knowledge and a top-down approach starting from the statistical
analysis of available data [18]. In a more detailed level, there are several ways to build and
illustrate a biological network [25]. Perhaps the most versatile and general way is the de novo
assembly of a network from direct experimental or computational interactions, e.g. chemi‐
cal/gene/protein screens. For the broad screening, the application of known interactions to
an omic data set either manually or by using pathway-analysis software (Ingenuity Pathway
Analysis, MetaCore, etc) has been widely used for hypothesis building and for identifying
crucial network components. The most direct way to employ time-honoured modelling and
simulation practices and more restricted and focused experimental datasets is by reverse en‐
gineering to generate a subset of networks ab initio. Most biochemical and regulatory path‐
ways have been built in the past via painstaking experimental work on a single or a few
components of a system, which has become understandable in toto only later in the research
process. Likewise, it has to be realised that the first assembly of a network is just the begin‐
ning of an iterative modelling-simulation-experimentation cycle and the final outcome may
be quite different from the original network.
Building a biologically relevant network needs a lot of relevant information. Indeed, emer‐
gence of systems biology and network analysis has occurred alongside with, and made pos‐
sible to a considerable extent by, the developments in various omic technologies, high-
throughput platforms, high-content screens, bioinformatics, and large-scale data handling
and storage [26]. Production of data on genes (genomics), transcripts (transcriptomics), pro‐
teins (proteomics), epigenetic changes, metabolites (metabolomics) has put forth the neces‐
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sary raw material for building networks which encompass biologically relevant nodes
(genes, proteins, metabolites), their connections (biochemical, regulatory), and modules
(pathways, functional units), which through iterative process can become an increasingly
relevant representation of real biological phenomena. On the other hand, the network analy‐
sis, once developed to a sufficient extent, offers a framework for data inclusion and interpre‐
tation by incorporating all pieces of information coming from earlier studies, current omics,
high-content and high-throughput screening experiments, expected or unspecific findings,
and these interpretations may lead to new experimental designs, both virtual and real.
Some experts envisage as a final goal the building of a virtual or in silico human [23]. Actual‐
ly leading systems biologists signed the so-called Tokyo declaration in February 2008, with
the aim for an in silico replica of a whole human body to be 90% complete by 2038. At the
present, there are quite a number of simulation packages as spatiotemporal representations
of various cellular functions [18].
5. Diseases as perturbations in biological networks
Many diseases, especially chronic ones, are initiated and perpetrated via dysregulation of
multiple pathways, even if the primary reason is the mutation in a central gene associated
with an endogenous or exogenous insult. The application of network analysis on human
diseases, especially on those associated with polymorphisms, but increasingly also on dis‐
eases not primarily associated with structural mutations, has made it increasingly clear that
chronic diseases demonstrate changes in expression of a large number of genes, proteins
and metabolites, involve a large number of modules or functional units and show considera‐
ble overlap of important genes and network modules [27-31]. Obvious implications of this
complexity are that single-target drugs may be completely inadequate to remedy a complex
situation, and efficiency of any drug could be highly dependent on importance (centrality)
of the target (“node” or “edge”) in the disease network. In this respect, studies on drug-tar‐
get networks suggest that many drugs developed earlier have rather peripheral targets in
the disease-associated networks whereas many more novel drugs are interacting with tar‐
gets closer to disease aetiology-linked components [32].
6. How to use network pharmacology in drug development?
Since the beginning of the genomic era, drug discovery process turned towards target based
approaches for a deceptively simple reason: an ever efficient identification of a large number
of potential targets for small and large molecules by the application of molecular biological
and pharmacogenomics tools. Expectations have been large, but still costs have increased
and the number of new medicinal entities stalled or decreased. Variable reasons for the in‐
creasing costs and a huge attrition even during clinical trials have been suggested, but many
experts have begun to claim that the currently popular target-based approach is basically
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flawed as a guide for drug discovery process. Instead, many authors have argued that sys‐
tems biology and polypharmacology encompassing network thinking should be adopted to
remedy the current difficulties in drug discovery and development. However, because net‐
work pharmacology is a relatively new concept, there is not too much robust data to demon‐
strate its superiority in drug development process. Yet some pieces of information seem to
point out that indeed network pharmacology is providing a new paradigm [12,33]. Some of
the current suggestions based on network pharmacology are compiled in Table 2.
Target Rationale Example
Molecular target
identification
Magic bullet aimed at target; if a target is a hub, the
consequence may be too much toxicity
Current paradigm
Edgetic perturbation Drug targeting towards a certain edge (connection)
of an intended target
Inherited disorders seem to separate
into node removal and edgetic-
specific variants [34]
Motifs, modules Drug targeting towards a common feature or a
functional unit of importance to disease (symptom
or aetiology)
Inhibitors of protein kinases with
common structural motifs in the
active site
Bridging nodes A target resulting in a modulation of crosstalk
between nodules, but not vital to cell function
No good example
Multi-targets Multiple disease-associated nodes, which can be
affected in an optimal manner without
compromising vital cellular functions
Anti-psychotics on multiple
transmitter-associated receptors
Table 2. Drug design, discovery, and repurposing potentialities of network pharmacology
Recently, Swinney & Anthony analysed preclinical discovery strategies that were used to
identify potential drug candidates, which were ultimately approved by the US Food and
Drug Administration (FDA) between 1999 and 2008 [35]. They classified strategies to target-
based screening, phenotypic screening, modification of natural substances and biologic-
based approaches, with an additional consideration on molecular mechanisms of action
(MMOA). Out of the 259 agents that were approved, 75 were first-in-class drugs with new
MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. They
claimed that the contribution of phenotypic screening to the discovery of first-in-class small-
molecule drugs exceeded that of target-based approaches — with 28 and 17 of these drugs
coming from the two approaches, respectively — in an era when the major focus was on tar‐
get-based approaches. They postulated that a target-centric approach for first-in-class drugs,
without consideration of an optimal MMOA, might contribute to the current high attrition
rates and low productivity in pharmaceutical research and development. Instead, among
follow-on drugs a vast majority were the outcomes of target-based approaches, which seem
rather natural considering that for these drugs mechanism of action and many other crucial
pieces of information could come much earlier and in more useful manner than for the first-
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in-class drugs. Actually the analysis of Swinney & Anthony concurs in many ways to the
findings of Yildirim et al [32], in that many recent new drugs are interacting with novel tar‐
gets thought to be more central in a corresponding disease aetiology, whereas follow-on
molecules tend to stick to well-known, often more peripheral targets, which are more distal
from core components of disease networks.
Although Swinney & Anthony did not specially mention network pharmacology (or corre‐
sponding) in their analysis, they refer to many crucial papers on network pharmacology. In
their analysis phenotypic screening means the use of functional assays, which usually in‐
form physiological parameters closer to real-life in vivo goals of drug therapy. Functional as‐
says associated with the elucidation of the molecular mechanisms of action are much closer
to the network analysis than the target-based screening. Intuitively it seems clear that func‐
tional assays are superior, at least from the drug discovery and development point of view,
than target-based assays. However, in reality target-centred thinking has been dominant for
more than a decade.
7. Properties of currently used drugs: Polypharmacology meets network
pharmacology
Even if the current paradigm has been 'one target (or disease/symptom)-one drug', practis‐
ing pharmacologists have always known that practically all drugs have multiple effects
based on various known or unknown mechanisms, some desirable and others indifferent or
harmful. A very good example is anti-psychotic drugs interacting with a large number of re‐
ceptors and other targets. One target-one drug paradigm created a vision of a “magic bul‐
let”, which was eagerly adopted, although some scientists pointed out that even such
“magic bullets” have pharmacokinetics-associated problems, e.g. potential drug-drug inter‐
actions, as well as structure-related problems such as allergic reactions. Now it is becoming
increasingly apparent that biological systems are complex, redundant, homeostatic and re‐
silient to perturbations and, consequently, most diseases are exhibiting much wider pertur‐
bations and variations than once thought. A new discipline, termed loosely as
polypharmacology, has been gaining ground both conceptually and experimentally.
It seems highly likely that most current drugs are interacting with multiple targets. Current
drug-protein interaction and chemogenomic studies have indicated that many drugs are in‐
teracting with two or more targets at reasonably close affinities. In these studies especially,
the database of the FDA-approved drugs and their targets (effects) have been employed to
create networks of drug-protein interactions [32,36] or to model similarities in chemical
structure between drugs and potential ligands for the prediction of drug-target interactions
[12, 37-38]. In Figure 1, a general approach to make use of the polypharmacology network is
outlined [11]. In this approach the polypharmacology network is mapped onto the biological
network, for example human disease-gene network, to reveal multiple actions of drugs on
multiple targets and multiple diseases [30].
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However, most of the studies on polypharmacology are based on computational and statisti‐
cal associations, although some of the major findings have been studied further experimen‐
tally [37,38]. For example, a recent study demonstrated that unknown and unexpected “off-
target” effects of many marketed drugs can be predicted by the computational analysis of
ligand-target interaction; some predictions were experimentally confirmed [39]. Especially
chemogenomic and chemoproteomic studies are based on direct or calculated affinities. It
should be pointed out that affinity is not a reaction or other immediate outcome, e.g. antago‐
nism, of an interaction and more distal functional or physiological consequences may or
may not occur for various reasons even if a primary interaction has been demonstrated or
predicted. Still clear evidence on functional consequences is required to be sure that an ac‐
tual pharmacological significance is demonstrated for a substance.
 
Figure 1. A network-centric view of drug action. Primary building blocks of network pharmacology are the drug-target
network (above) and the biological network (below). The network in the centre is a part of the biological network in which
proteins (nodes) targeted by the same drug are represented in the same colour. Consequently drug efficacy and toxicity
can be understood by action at specific nodes and hubs. For the definition of nodes and hubs, see Table 1. The figure is re‐
printed by permission from Macmillan Publishers Ltd: [Nature Biotechnology] (11), copyright (2007).
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Recently, a polypharmacological approach has been extended to include functional consid‐
erations. Simon et al [40] employed 1177 FDA-approved small molecular drugs by investi‐
gating interaction profiles based on in silico docking/scoring methods to a series of virtual
non-target protein binding sites and contrasting these profiles with 177 major drug catego‐
ries of the same series of FDA-approved drugs. Statistical analyses confirmed a close rela‐
tionship between the studied effect categories and interaction profiles of small molecule
drugs. On the basis of this relationship, the comprehensive effect profiles of drugs were ap‐
parent and furthermore, effects not previously associated with particular drugs could be
predicted. A rather curious finding – which is not easily explained by classical pharmacolog‐
ical concepts – was that the prediction power was independent of the composition of the
protein set used for interaction profile generation. Perhaps general chemical and physico‐
chemical properties of molecules are of importance for potential interactions in general,
whereas pharmacophores, i.e. specific stereochemical groups, are crucial for specific high-
affinity interactions.
8. Systems toxicology
Network approach helps to understand and reveal on-target and off-target toxicity of phar‐
maceuticals, but it also helps to delineate the toxicities of any chemicals, be they industrial
chemicals, agrochemicals, cosmetics, environmental pollutants, etc. Omic approaches pro‐
vide voluminous information about time-dependent changes at various levels of biological
complexity after the administration of a chemical and provide the so-called signatures of
toxicity. On the other hand, the application of known and characterised toxicants has de‐
lineated a finite number of pathways of toxicity. Bringing this information together at the
established network and systems level would create a 'systems toxicology' approach, analo‐
gous to systems pharmacology and polypharmacology [41].
9. Physiologically based pharmacokinetic (PBPK) modelling
A relatively isolated area in pharmacology and toxicology is the model building to describe
the behaviour and disposition of drugs and other chemicals in the body [42]. Especially
those models that make use of physiological principles resemble in many ways network
pharmacology. Whole body PBPK models consist of absorption sites and manners, tissues
with membranes drugs and their metabolites have to cross, with special reference to tissues
which metabolise and excrete drugs and their metabolites, and so on. Concentrations of a
studied chemical (and its important metabolites) in these various compartments could be
equated to nodes. Connections are permeation and corresponding constants (for passive and
active processes in the membranes and other cellular barriers, distribution coefficients, enzy‐
matic reactions (clearance), and so on. Although the number of building blocks in pharma‐
cokinetic models is finite and certainly much less than in most systems pharmacology
networks, models have become quite complex, but still useful for predicting the behaviour
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of a drug in the body under various circumstances. Efforts to link PBPK models with in vi‐
tro-in vivo extrapolations under the systems pharmacology umbrella are underway [43].
Whole-body PBPK models illustrate also important challenges to, and potentialities of, net‐
work pharmacology. First of all, the framework for modelling is multi-scale [44], starting
from enzymes and transporters (dealing with transformation and movement of drugs) and
their quantitative functions (clearance, metabolite formation, membrane penetration) and
their regulation and functions in the cells and tissues, kinetics of drugs and their metabolites
throughout the body via circulation, distribution to different organs, elimination in urine, in
bile, and integration of all processes into a dynamic model representing an individual (in sil‐
ico human or animal, for that matter) and extending the modelling to evolution, develop‐
ment, environment, populations, diseases, etc. PBPK modelling is increasingly used in drug
development and toxicity risk assessment with considerable success, probably because it is a
rather restricted in dealing with behaviour of a single substance in the framework of a finite
number of active players. On the other hand, pharmacodynamic models that have been de‐
veloped for at least a couple of decades are closer to network building (ab initio models).
10. TCM network pharmacology & “network targets” for TCM drugs
In 2010, Liu & Du raised the concept of “TCM network pharmacology”, linking the multiple
components that play principal, complementary and assistant therapeutic roles in TCM for‐
mulae to principal, complementary and assistant targets in a disease network. They believed
that such an approach to projecting a TCM drug component network onto a disease network
offers a novel philosophical guide and technological route to designing and understanding
mechanisms of action of TCM drugs and is thus likely proven important in modernisation of
TCM [45]. Similarly, Li emphasised “network targets” of systems, connectivity and predic‐
tiveness features in studying TCM formulae and syndromes and the work of his team
showed that the “network target” approach could facilitate discovery of effective com‐
pounds, understanding their interrelation, elucidating relationship between TCM formulae
and diseases or TCM syndrome, developing rational TCM drug, as well as guiding integrat‐
ed use of TCM and conventional drugs [46].
TCM network pharmacology heavily relies on omic platforms as well as algorithm- and net‐
work-based computational tools, which are elegantly summarised most recently by Leung et
al [47]. In addition, TCM network pharmacology heavily relies on ever updating omics,
pharmacological and TCM-related databases. While concerns about duplication of efforts,
poor standardisation and low sustainability remain, many TCM databases have been devel‐
oped, as recently reviewed by Barlow et al [48]. To mention a few, the Chem-TCM database
developed by King’s College London [49] has now been commercialised by TimTec LLC
(http://www.chemtcm.com); the trial version of World Traditional & Natural Medicine Pat‐
ent Database is currently being developed by Beijing East Linden Co. Ltd (http://www.east‐
linden.net/NewsShow.aspx?news_id=20081127102018850246); and the Herbal Ingredient
Target database (HIT: http://lifecenter.sgst.cn/hit/) and the TCM Information Database
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(TCM-ID: http://tcm.cz3.nus.edu.sg/group/tcm-id/tcmid_ns.asp) have been developed by
academics based in China and Singapore [50,51].
11. Applications of TCM network pharmacology
In TCM, formulae are usually prescribed based on TCM syndrome patterns of a given pa‐
tient, rather than a disease as defined in Western medicine. Thus, an important part of TCM
network pharmacology is to establish links between network molecular targets and TCM
syndrome patterns. Ma et al surveyed 4575 cases of Cold Syndrome patients and examined
gene expression information of a typical Cold Syndrome pedigree by microarray. Results in‐
dicated that Cold Syndrome related genes played an essential role in energy metabolism,
which were tightly correlated with the genes of neurotransmitters, hormones and cytokines
in the neuro-endocrine-immune interaction network [52]. In TCM clinics, Cold Syndrome is
treated by Warm formulae and Hot Syndrome is often treated by Cold formulae. Identifica‐
tion of the gene networks of Cold and Hot Syndromes [52, 53-55] should help understand
nature of a condition and unravel mechanisms of its related TCM treatment [56].
In addition, Wang and colleagues (2011) proposed that network pharmacology could be ap‐
plied to the following aspects of TCM studies:
11.1. “Disease-gene-target” network-based studies to identify targets and pathways
affected by TCM drugs and to obtain fuller pictures of the efficacy and mechanisms of
action of TCM drugs
Sun  et  al  performed  bioinformatic  analysis  of  anti-Alzheimer's  herbal  medicines  and
found that ingredients of  anti-Alzheimer’s herbs not only bound symptom-relieving tar‐
gets,  but  also  interact  closely  with  a  variety  of  successful  therapeutic  targets  related  to
other diseases, such as inflammation, cancer and diabetes,  suggesting the possible cross‐
talk between these complicated diseases.  Furthermore, the anti-Alzheimer's herbal ingre‐
dients  densely  targeted  pathways  of  Ca2+  equilibrium  maintaining  upstream  of  cell
proliferation and inflammation [57].
Wen et al used microarray and network analysis to establish that Si-Wu-Tang is an Nrf2 ac‐
tivator and phytoestrogen, thus suggesting its use as a nontoxic chemopreventive agent [58].
In fact, network analysis of all sorts of omic data can be used to explore the molecular tar‐
gets and mechanisms of action of TCM drugs [59,60], as recently reviewed by Buriani et al
[8]. In network pharmacology, roles for functional genes and proteins might vary in differ‐
ent stages of the same disease, thus the same disease could be treated differently, as em‐
phasised in TCM; on the other hand, some functional proteins are “hubs” in the disease
networks of more than one disease, thus different diseases could be treated similarly by tar‐
geting the same hubs [45]. Based on gene and phenotype information associated with the
ingredient herbs of the classical Liu-wei-di-huang (LWDH) formula and LWDH-treated dis‐
eases, it was found that LWDH-treated diseases showed high phenotype similarity and
identified certain "co-modules" enriched in cancer pathways and neuro-endocrine-immune
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pathways, which may be responsible for the action of treating different diseases by the same
LWDH formula [61].
11.2. Construction of “TCM drugs-targets-diseases” network and elucidation of the
scientific base of TCM drug formulation through network analysis
Zheng et al studied the interactions between 514 compounds contained in a Chinese herbal
formula Jingzhi Tougu Xiaotong Granule (JZTGXTG) and 35 drug targets of relevance to os‐
teoarthritis and the distribution of 514 compounds in drug-target space. By analysing pa‐
rameters of the JZTGXTG compound-target interaction network and the drug-target
interaction network including network heterogeneity and characteristic path length, the re‐
sults illustrated the possible molecular mechanisms of JZTGXTG in the prevention and
treatment of osteoarthritis at the network pharmacology level [62].
To predict multi-targets by multi-compounds found in Aconiti Lateralis Radix Praeparata,
Wu et al constructed the corresponding multi-compound-multi-target network based on the
drug-target relationship of FDA approved drugs. The predicted targets of 22 compounds of
Aconiti Lateralis Radix Praeparata were validated by literature. Each compound in the es‐
tablished network was correlated with 16.3 targets on average, while each target was corre‐
lated with 4.77 compounds on average, which reflected the "multi-compound and multi-
target" characteristic of TCM drugs [63].
A "network target” approach has been applied to virtual screening and established an algo‐
rithm known as network target-based identification of multicomponent synergy (NIMS) to
prioritise synergistic combinations of agents in a high-throughput manner [64]. From a “net‐
work target” perspective, a method called distance-based mutual information model
(DMIM) was established to identify useful relations among herbs in numerous herbal for‐
mulae and a novel concept of "co-module" across herb-biomolecule-disease multilayer net‐
works was proposed to explore the potential mechanisms of herbal formulations [61].
DMIM, when used for retrieving herb pairs, achieved a good balance among the herb's fre‐
quency, independence, and distance in herbal formulae. A herb network constructed by
DMIM from 3865 collaterals-related herbal formulae not only recovered traditionally de‐
fined herb pairs and formulae, but also generated novel anti-angiogenic herb ingredients
and herb pairs with synergistic or antagonistic effects [61].
Li et al constructed a network of nine major active compounds from Fufang Danshen formu‐
la, their multi-targets and multiple related diseases. The nine compounds were tanshinone II
A, salvianolic acid B, protocatechuic aldehyde, danshensu, cryptotanshinone, notoginseno‐
side R1, ginsenoside Rg1, ginsenoside Rb1 and borneol. Network analysis showed that these
compounds could modulate 42 genes associated with cardiovascular diseases (e.g. PPARG,
ACE, KCNJ11, KCNQ1 and ABCC8), which were related to 30 clinical conditions, including
non-insulin-dependent diabetes mellitus, hyperinsulinaemic hypoglycaemia, hypertension
and coronary heart disease [65].
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11.3. Building “TCM drug properties-clinical indications-adverse effects” networks and
illustrating the relationship between TCM drug properties and efficacy
Jia et al analysed 117 drug combinations and identified general and specific modes of action
and highlighted the potential value of molecular interaction profiles in the discovery of nov‐
el multicomponent therapies [66].
Zhu et al performed network analysis of 2215 chemicals identified in 62 Chinese herbs indi‐
cated for patients with chronic kidney diseases, including 836 chemicals contained in 22 to‐
nifying herbs and 1379 chemicals contained in 40 evil-expelling herbs, according to TCM
theory, in comparison with 99 drugs used in conventional medicine. Interaction networks of
tonifying herbs, evil-expelling herbs and drugs showed different patterns, regarding net‐
work parameters, especially network degree, average number of neighbours and character‐
istic path lengths and shortest paths [67].
Wu et al constructed a relational network of TCM decoction slices to discover and interpret
the correlations between the natures and functions of decoction slices and their clinically in‐
dicated symptoms and channel tropism as defined in TCM. 3016 pairs of decoction slice-
symptom correlation associated with 646 decoction slices were discovered [68].
11.4. Evaluation of the safety, efficacy and stability of TCM products through
constructing network models and network analysis
Emerging studies have supported the potential for network pharmacology in quality control
of TCM drugs [69], which can well interpret the mechanisms of action of TCM drugs [70],
help understand how different constituents of a TCM formulation and how TCM and chem‐
ical drugs synergised through targeting different nodes in disease-related networks [71,72].
There is no regulatory requirement of omics-based data in any submitted dossier to any reg‐
ulatory agency, including for TCM products. However, it has been acknowledged that such
studies are being increasingly performed, and almost surely will eventually be included into
regulatory submission dossiers, possibly initially as supplementary materials [9]. Such a
prospect is likely also shared with systems and network pharmacology.
12. Inspirations and challenges that TCM has to offer to network
pharmacology
12.1. More networks
In network pharmacology, “network” refers to the molecular network in a targeted organ‐
ism, for instance the “network targets” in patients. In TCM network pharmacology, howev‐
er, complex TCM drugs themselves become another important molecular network, which
might be called “network bullets” that interact with “network targets” in order to help the
body to regain balance. Importantly, some components of TCM drugs are not to target “net‐
work targets”, but to target other drug components, so as to alleviate their side-effects, im‐
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prove activity of the principal drug component, improve absorption and/or facilitate
delivery of the principal drug to the targeted disease areas. Thus, TCM network pharmacol‐
ogy involves at least two networks to be considered in modelling and analysis.
In TCM, as guided by TCM theories, it is of paramount importance to choose a number of
herbs (sometimes also zoological or mineral components) based on particular symptoms
and characteristics of a patient. To assemble a formula or fangji, principal and enabling herbs
are combined in order to optimise the effectiveness and minimise adverse effects. The prin‐
cipal herbs are known as the jun herbs, which treat the main cause or primary symptoms of
a disease. The enabling herbs include the chen herbs, which serve to augment or broaden the
effects of jun herbs and to relieve secondary symptoms; zuo herbs, which modulate the ef‐
fects of jun and chen herbs and to counteract the toxic or side effects of these herbs; and the
shi herbs, which function to facilitate absorption and delivery of active herbal components to
the target organs. Thus, the combination of principal (Jun) and enabling (Chen, Zuo and/or
Shi) components to form a drug network could form the basis for designing novel “network
bullets” in the future application of network pharmacology.
12.2. More holistic
Network pharmacology aims to research and develop drugs holistically. However, the current
model of network pharmacology that focuses on psychological and somatic diseases separate‐
ly could be improved if it is to meet requirements of the psychosomatic model of health and ail‐
ments. Specifically, in addition to the well-known placebo effects of any interventions, the
pathological damage of emotions to the internal organs is of primary concern of TCM practi‐
tioners. We propose that psychosomatic factors should be linked up in the next generation of
network pharmacology and emotions should be included in the equations of future network
analysis. By doing so, research might eventually help unravel and harness placebo effects and
tackle psychosomatic ailments in a network pharmacological perspective.
12.3. More individualised
Personalised medicine is gaining momentum [73-75]. Network pharmacology needs to catch
up with this trend as well. In TCM, individualisation goes beyond personalisation, because
the same person at different ages, on different diets or living style, under different weather
condition and at the different phases of the same disease could be diagnosed and treated
differently. Can network pharmacology not only be personalised but also individualised,
taking all the above variations into account?
13. Conclusions and perspectives
According to Paul Unschuld, a renowned German sinologist, cultural background has a
great impact on the preferred directions of medical science. For example, both in ancient
Greece and China philosophers came up with the idea of "relationist science" or "science of
systematic correspondences" on the one hand and "analytical science" on the other. While in
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ancient Europe relationist science was soon marginalised and analytical science became the
approach of choice, in ancient China the beginnings of an analytical perspective were not
pursued further and relationist science became the approach of choice [76]. Nowadays, the
post-genomic era is characterised by globalisation and digitalisation. While omic data repre‐
sent the state of the art of the analytical power of Western science, these data could be mean‐
ingless “sacs of data” unless they are linked up functionally using a relationist approach. At
this point, the dominant approaches in the West and East are integrated to relate pieces of
fragmented omic data and their functions and this might well serve as a bridge of both med‐
ical traditions. Analyses of state-of-the-art modern and TCM pharmacological and toxicolog‐
ical research data appear to support the concept of network pharmacology, i.e. a systems
network-based model can help better understand health, disease and how Western medi‐
cine, TCM drugs or integrated TCM and Western medicine work. It can be expected that this
approach could play a more important role in research and development of new drugs and
in helping understand the mechanisms of action of drugs, especially in TCM.
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